• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?他达拉非能否预防接受前列腺癌放射治疗患者的勃起功能障碍？
Asian J Androl. 2014 Sep-Oct;16(5):664-5. doi: 10.4103/1008-682X.133324.
2
Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.他达拉非预防前列腺癌放射治疗后勃起功能障碍的效果：放射治疗肿瘤学组 [0831] 随机临床试验。
JAMA. 2014 Apr 2;311(13):1300-7. doi: 10.1001/jama.2014.2626.
3
Prevention of erectile dysfunction after radiotherapy for prostate cancer.前列腺癌放疗后勃起功能障碍的预防
Asian J Androl. 2014 Nov-Dec;16(6):805-6. doi: 10.4103/1008-682X.133327.
4
Words of wisdom. Re: Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the radiation therapy oncology group [0831] randomized clinical trial.智慧之言。关于：他达拉非用于预防前列腺癌放疗后勃起功能障碍：放射治疗肿瘤学组[0831]随机临床试验。
Eur Urol. 2014 Sep;66(3):594-5. doi: 10.1016/j.eururo.2014.06.029.
5
Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer.他达拉非用于前列腺癌放疗后勃起功能障碍的预防。
JAMA. 2014 Aug 20;312(7):748. doi: 10.1001/jama.2014.7920.
6
Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer--reply.他达拉非用于前列腺癌放疗后勃起功能障碍的预防——回复
JAMA. 2014 Aug 20;312(7):748-9. doi: 10.1001/jama.2014.7923.
7
A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.一项随机、双盲、安慰剂对照、交叉研究，旨在评估他达拉非（希爱力）在前列腺癌三维适形外照射放疗后治疗勃起功能障碍的疗效。
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):439-44. doi: 10.1016/j.ijrobp.2006.04.047.
8
Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.按需服用他达拉非 20 毫克与每日一次服用他达拉非 5 毫克治疗前列腺癌放疗后勃起功能障碍的疗效和安全性：一项随机 II 期试验。
J Sex Med. 2010 Aug;7(8):2851-9. doi: 10.1111/j.1743-6109.2010.01890.x.
9
Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil.前列腺近距离放射治疗及低剂量他达拉非后的性功能保留与生活质量
Brachytherapy. 2015 Mar-Apr;14(2):160-5. doi: 10.1016/j.brachy.2014.08.045. Epub 2014 Sep 23.
10
Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial.他达拉非（希爱力）与前列腺癌放疗后的勃起功能障碍：一项双盲试验的开放标签扩展研究。
Urology. 2007 Dec;70(6):1190-3. doi: 10.1016/j.urology.2007.08.029.

引用本文的文献

1
Radiotherapy for prostate cancer and sexual health.前列腺癌放疗与性健康。
Transl Androl Urol. 2015 Apr;4(2):124-30. doi: 10.3978/j.issn.2223-4683.2014.12.08.

本文引用的文献

1
Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.他达拉非预防前列腺癌放射治疗后勃起功能障碍的效果：放射治疗肿瘤学组 [0831] 随机临床试验。
JAMA. 2014 Apr 2;311(13):1300-7. doi: 10.1001/jama.2014.2626.
2
A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer.一项关于每晚服用枸橼酸西地那非以保留前列腺癌放射治疗后勃起功能的随机、双盲、安慰剂对照试验。
J Med Imaging Radiat Oncol. 2013 Feb;57(1):81-8. doi: 10.1111/j.1754-9485.2012.02461.x. Epub 2012 Oct 18.
3
Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.按需服用他达拉非 20 毫克与每日一次服用他达拉非 5 毫克治疗前列腺癌放疗后勃起功能障碍的疗效和安全性：一项随机 II 期试验。
J Sex Med. 2010 Aug;7(8):2851-9. doi: 10.1111/j.1743-6109.2010.01890.x.
4
Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215.随机、双盲、安慰剂对照交叉试验，用西地那非治疗放射治疗和短期雄激素剥夺治疗后的勃起功能障碍：RTOG 0215 的结果。
J Sex Med. 2011 Apr;8(4):1228-38. doi: 10.1111/j.1743-6109.2010.02164.x. Epub 2011 Jan 14.
5
Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.每晚服用伐地那非与按需服用伐地那非对双侧保留神经的根治性前列腺切除术后男性勃起功能恢复的影响。
Eur Urol. 2008 Oct;54(4):924-31. doi: 10.1016/j.eururo.2008.06.083. Epub 2008 Jul 9.
6
Penile rehabilitation should become the norm for radical prostatectomy patients.阴茎康复应成为根治性前列腺切除术患者的常规治疗。
J Sex Med. 2007 May;4(3):538-543. doi: 10.1111/j.1743-6109.2007.00486.x.
7
Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.近距离放射治疗后早期使用磷酸二酯酶抑制剂可恢复并保留勃起功能。
BJU Int. 2006 Dec;98(6):1255-8. doi: 10.1111/j.1464-410X.2006.06441.x.
8
A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.一项随机、双盲、安慰剂对照、交叉研究，旨在评估他达拉非（希爱力）在前列腺癌三维适形外照射放疗后治疗勃起功能障碍的疗效。
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):439-44. doi: 10.1016/j.ijrobp.2006.04.047.
9
Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostate cancer.
Urology. 2002 Jul;60(1):1-7. doi: 10.1016/s0090-4295(02)01659-x.
10
Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study.枸橼酸西地那非（万艾可）与前列腺癌外照射放疗后的勃起功能障碍：一项随机、双盲、安慰剂对照、交叉研究。
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1190-5. doi: 10.1016/s0360-3016(01)01767-9.

他达拉非能否预防接受前列腺癌放射治疗患者的勃起功能障碍？

Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?

作者信息

Incrocci Luca

机构信息

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, 3000 CA, The Netherlands.

出版信息

Asian J Androl. 2014 Sep-Oct;16(5):664-5. doi: 10.4103/1008-682X.133324.

DOI:10.4103/1008-682X.133324
PMID:24969064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4215677/
Abstract

A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer. Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.

摘要

最近发表的一篇论文探讨了一个有趣的话题

在接受局限性前列腺癌放射治疗的患者中，使用磷酸二酯酶5型抑制剂（PDE5i）他达拉非预防勃起功能障碍（ED）。对于接受前列腺癌外照射放疗（EBRT）或近距离放疗（BT）的患者，每天服用一次5毫克他达拉非或安慰剂，持续24周。这项随机试验显示，在停止研究药物4至6周后，与安慰剂相比，活性药物并无更高的疗效。此外，65岁以下的患者与老年患者相比，反应并没有明显更好。